

Artikel 109 lid 2 MDR

Fra: 5.1.2e <5.1.2e@fimea.fi>

Sendt: 6. juni 2023 08:45

Til: 5.1.2e (FAGG - AFMPS) <5.1.2e@fagg-afmps.be>; 5.1.2e@ec.europa.eu;
5.1.2e@basg.gv.at; 5.1.2e@bda.bg; 5.1.2e@miz.hr; 5.1.2e@halmed.hr; 5.1.2e@mphs.moh.gov.cy;
5.1.2e@sukl.cz; Med-udstyr 5.1.2e@dkma.dk>; 5.1.2e@terviseamet.ee; 5.1.2e <5.1.2e@fimea.fi>; 5.1.2e@ansm.sante.fr;
5.1.2e@zlg.nrw.de; 5.1.2e@eof.gr; 5.1.2e@eof.gr; 5.1.2e@igj.nl; 5.1.2e@ogyei.gov.hu;
5.1.2e@ima.is; 5.1.2e@hpra.ie; 5.1.2e@sanita.it; 5.1.2e@vi.gov.lv; 5.1.2e@lv.li;
5.1.2e@vaspvt.gov.lt; 5.1.2e@ms.etat.lu; 5.1.2e@gov.mt; 5.1.2e@noma.no;
5.1.2e@urpl.gov.pl; 5.1.2e@infarmed.pt; 5.1.2e@anm.ro; 5.1.2e@sukl.sk; 5.1.2e@jazmp.si; 5.1.2e@jazmp.si;
5.1.2e@aemps.es; 5.1.2e@lakemedelsverket.se; 5.1.2e@titck.gov.tr

Cc: 5.1.2e (FAGG - AFMPS) <5.1.2e@fagg-afmps.be>; 5.1.2e (FAGG - AFMPS) <5.1.2e@fagg-afmps.be>

Emne: RE: 230522_BE_New Gene COVID-19 antigen test_NL PL All_R_FI

Dear colleague,

Please find attached Finland's response to your CEF.

Best Regards,

5.1.2e
5.1.2e
Tel. 5.1.2e
5.1.2e@fimea.fi

fimea

The information contained in this message may be legally privileged and confidential and protected from disclosure. Any unauthorized use, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by replying to the message and deleting it from your computer.

5.1.2e

Dubbel met ID 8511371

Dubbel met ID 8511371